ARCH Venture Partners
About ARCH Venture Partners
Early stage venture capital firm focused on the bio-medical, physical, materials and computational sciences.
Recent News
Aspen Neuroscience Lands $115M Series C
Resolve AI Raises $125M in Series A Funding at $1B Valuation
The Longevity Startup That Already Has the Data Altos Labs Is Seeking: Hidden in Plain Sight
Elephas Biosciences Receives $40M Series B-2
Lifordi Immunotherapeutics Inks New Funding
Gate Bioscience Raises $65M in Series B Financing
BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets
Vizgen Raises $48M in Funding
Recent Deals
Aspen Neuroscience Secures $115M Series C Funding
Pelage Pharmaceuticals Closes $120M Series B Led by ARCH Venture Partners and GV
Kardigan Raises $254M Series B to Advance Cardiovascular Drug Development
Gate Bioscience Secures $65M Series B Round Led by Forbion and Eli Lilly
Paradigm Health Secures $78M Series B Led by ARCH Venture Partners
Elephas Biosciences Secures $40M Series B-2 Funding to Advance Live Tumor Profiling Platform
SciNeuro Pharmaceuticals Secures $53M Equity Financing
Pelage Pharmaceuticals Raises $120M in Series B Co-Led by ARCH and GV
Synchron Raises $200M in Series D Round
Lifordi Immunotherapeutics Secures Strategic Investment From Sanofi Ventures, Raising Total to $112M
